Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Inhibrx Biosciences (INBX) Profit After Tax: 2023-2024

Historic Profit After Tax for Inhibrx Biosciences (INBX) over the last 2 years, with Dec 2024 value amounting to $1.7 billion.

  • Inhibrx Biosciences' Profit After Tax rose 19.62% to -$35.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$155.1 million, marking a year-over-year decrease of 109.45%. This contributed to the annual value of $1.7 billion for FY2024, which is 799.19% up from last year.
  • Inhibrx Biosciences' Profit After Tax amounted to $1.7 billion in FY2024, which was up 799.19% from -$241.4 million recorded in FY2023.
  • Over the past 5 years, Inhibrx Biosciences' Profit After Tax peaked at $1.7 billion during FY2024, and registered a low of -$241.4 million during FY2023.
  • Moreover, its 2-year median value for Profit After Tax was $723.1 million (2023), whereas its average is $723.1 million.
  • Data for Inhibrx Biosciences' Profit After Tax shows a peak YoY spiked of 799.19% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Inhibrx Biosciences' Profit After Tax stood at -$241.4 million in 2023, then spiked by 799.19% to $1.7 billion in 2024.